
|Articles|October 1, 2002
Verteporfin trial tests more frequent doses
Vancouver, Canada-QLT and Novartis are running a new phase IIIB trial of verteporfin (Visudyne) to determine whether better outcomes occur if CNV leakage is treated with a more aggressive treatment regimen in the first 6 months.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement




























